Evogene Ltd. has made significant changes in its management team, which could impact its strategic direction in the agricultural chemicals sector. The company has appointed Dr. Adi Zuluf-Shani as the new Chairperson of the Board, effective November 18, 2026. Additionally, Mr. Rephael Haim will take over as VP Finance, starting November 22, 2026, following the resignation of Ms. Polina Ravzin.

Evogene Ltd. is a company focused on the agricultural chemicals sector, specifically involved in developing innovative solutions to enhance crop productivity. The firm is traded on the Nasdaq under the ticker symbol EVGN. As a non-accelerated filer, Evogene has been active in filing various reports with the SEC, including recent filings that detail its operational updates and strategic moves.

The recent filing indicates that Ms. Ravzin's resignation is due to personal reasons and is not linked to any disagreements with the company. In her place, Mr. Haim brings a wealth of experience, having previously served as Head of Financial Planning and Analysis at Nanox Imaging and as VP Finance at Questar Auto Technologies. Notably, he was also a controller at Evogene from 2019 to 2022.

Evogene expressed gratitude to Ms. Ravzin for her contributions during her tenure and extended best wishes to Dr. Zuluf-Shani and Mr. Haim in their new roles. This leadership transition may influence the company's operations and strategic initiatives moving forward.

The filing does not say what happens next.